NFL Biosciences
Develops botanical drug candidates to treat smoking and alcohol addictions.
ALNFL | PA
Overview
Corporate Details
- ISIN(s):
- FR0014003XO1 (+1 more)
- LEI:
- 9695006VJWNTN4UNHA27
- Country:
- France
- Address:
- 199 RUE HELENE BOUCHER, 34170 CASTELNAU-LE-LEZ
- Website:
- https://www.nflbiosciences.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
NFL Biosciences is a biopharmaceutical company that develops botanical drug candidates for the treatment of addictions. The company's lead asset is NFL-101, an innovative drug candidate for smoking cessation derived from a nicotine-free protein extract of tobacco leaves. Its pipeline also includes NFL-301, a candidate aimed at reducing excessive alcohol consumption. NFL Biosciences operates with an outsourced research model, focusing on advancing its products through preclinical and clinical studies. The company's primary business strategy is to license its developed drug candidates to larger pharmaceutical companies for final commercialization.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-04-15 18:00 |
NFL Biosciences annonce la mise à disposition de son rapport financier annuel 2…
|
French | 179.3 KB | ||
| 2025-04-11 17:45 |
NFL Biosciences presents its 2024 annual results and provides an update on its…
|
English | 346.5 KB | ||
| 2025-04-11 17:45 |
NFL Biosciences présente ses résultats annuels 2024 et fait le point sur son pr…
|
French | 311.1 KB | ||
| 2025-03-24 17:45 |
NFL Biosciences présente les résultats de l'analyse immunologique de son étude …
|
French | 253.1 KB | ||
| 2025-03-24 17:45 |
NFL Biosciences presents the immunological analysis results of its phase 2 CEST…
|
English | 258.5 KB | ||
| 2025-03-05 17:45 |
NFL Biosciences publie son agenda financier 2025
|
French | 176.4 KB | ||
| 2025-03-05 17:45 |
NFL Biosciences publishes its 2025 financial agenda
|
English | 190.6 KB | ||
| 2025-01-10 17:45 |
NFL BIOSCIENCES : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ DU 2ème SEMESTRE 2024
|
English | 2.2 MB | ||
| 2024-12-05 08:02 |
NFL BIOSCIENCES VALIDATES THE INDUSTRIALIZATION OF NFL-101 FOR SMOKING CESSATION
|
English | 507.8 KB | ||
| 2024-12-05 08:02 |
NFL BIOSCIENCES VALIDE L’INDUSTRIALISATION DE NFL-101 POUR LE SEVRAGE TABAGIQUE
|
French | 655.4 KB | ||
| 2024-11-18 17:45 |
NFL BIOSCIENCES : LE MÉCANISME D’ACTION NOUVEAU ET DISRUPTIF DE NFL-101 POUR LE…
|
French | 531.6 KB | ||
| 2024-10-18 08:00 |
NFL BIOSCIENCES: LEADERSHIP TEAM PREPARING THE NEXT STAGES IN ITS DEVELOPMENT
|
English | 318.5 KB | ||
| 2024-10-18 08:00 |
NFL BIOSCIENCES : L’ÉQUIPE DIRIGEANTE PRÉPARE LES PROCHAINES ÉTAPES DU DÉVELOPP…
|
French | 448.7 KB | ||
| 2024-10-08 08:00 |
NFL BIOSCIENCES: EFFICACY VALIDATED THROUGH UPDATED ANALYSES FROM CESTO II FOR …
|
English | 1.1 MB | ||
| 2024-10-08 08:00 |
NFL BIOSCIENCES : VALIDATION DE L’EFFICACITÉ PAR DES ANALYSES ACTUALISÉES DE CE…
|
French | 1.2 MB |
Automate Your Workflow. Get a real-time feed of all NFL Biosciences filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for NFL Biosciences
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for NFL Biosciences via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
